Metronome LLC v. Sunset Novelties: Cannabis Patent Case Ends in Voluntary Dismissal

A cannabis-derived topical treatment patent infringement case filed in Florida’s Southern District Court concluded with a voluntary dismissal with prejudice — one of litigation’s most definitive procedural endings — just 103 days after it began. In *Metronome, LLC v. Sunset Novelties USA LLC* (Case No. 0:25-cv-61440), the plaintiff chose to exit the dispute permanently rather than pursue its infringement claims to resolution, raising strategic questions that patent attorneys and IP professionals in the rapidly evolving cannabis therapeutics space should closely examine.

Filed on July 16, 2025, and closed October 27, 2025, this cannabis patent infringement case centered on U.S. Patent No. US10653736B2, covering topical treatments incorporating cannabis-derived botanical drug products. The swift conclusion — achieved without a merits ruling — offers meaningful insights into assertion strategy, litigation risk management, and the competitive dynamics of cannabis IP, a technology area experiencing intensifying patent activity as the industry matures.

Case Overview

The Parties

The Patent at Issue

This case centered on U.S. Patent No. US10653736B2, covering topical treatments incorporating cannabis-derived botanical drug products:

• • US10653736B2 — Topical treatments incorporating cannabis-derived botanical drug products
• • Application Number: US16/257389
• • Technology Area: Topical treatments incorporating cannabis sp. derived botanical drug products

US10653736B2 claims formulations and methods related to cannabis-derived botanical drug substances applied topically — a commercially significant category spanning CBD creams, balms, and dermatological preparations. Patents in this space often involve complex claim landscapes addressing concentration thresholds, carrier formulations, and regulatory classifications aligned with FDA botanical drug guidance.

The Accused Product(s)

The complaint targeted Sunset Novelties’ topical treatments incorporating cannabis-derived botanical ingredients. Commercially, the cannabis topical market represents a high-growth segment, making IP disputes in this category consequential for market positioning and distribution rights.

Legal Representation

• • Plaintiff’s Counsel: Isaac Rabicoff (Rabicoff Law LLC) and Terry Marcus Sanks (Beusse Sanks PLLC)
• • Defendant’s Counsel: George Albert Minski (Law Offices of George A. Minski, P.A.)

Rabicoff Law LLC is a recognized plaintiff-side patent litigation firm with national reach. Beusse Sanks PLLC brings Florida-rooted IP litigation depth. The defense was represented by a Florida-based boutique practice with local district court familiarity.

The Verdict & Legal Analysis

Litigation Timeline & Procedural History

The case was filed in the **U.S. District Court for the Southern District of Florida** — a venue known for active commercial litigation dockets and proximity to Florida’s growing cannabis and wellness industry corridor. The Southern District has developed increasing familiarity with IP disputes in health and consumer product categories.

At 103 days from filing to closure, this case never reached claim construction, summary judgment briefing, or trial. The procedural record reflects that all pending motions were denied as moot upon the plaintiff’s filing of a Notice of Voluntary Dismissal with Prejudice (Docket Entry [17]).

The rapid timeline suggests the parties either reached an undisclosed resolution — a licensing agreement, covenant not to sue, or business-level settlement — or Metronome independently determined that continued litigation was strategically inadvisable given the evidentiary, legal, or commercial landscape it confronted after filing.

Outcome

On **October 27, 2025**, the Southern District of Florida entered an order closing the case following Metronome’s filing of a **voluntary dismissal with prejudice**. The court’s order, issued in West Palm Beach, directed the Clerk to close the case and denied all pending motions as moot.

A dismissal *with prejudice* is legally significant: unlike a without-prejudice dismissal, it permanently bars Metronome from reasserting the same claims against Sunset Novelties based on US10653736B2. No damages award, no injunctive relief, and no merits ruling were issued.

Verdict Cause Analysis

The basis of termination — voluntary dismissal — means the court never adjudicated infringement, validity, or claim scope. The legal record does not reflect a judicial finding favoring either party on the merits.

Several strategic factors typically motivate a plaintiff to file a with-prejudice voluntary dismissal this early in litigation:

• Pre-litigation resolution: The parties may have privately negotiated a licensing arrangement or settlement, with dismissal serving as the procedural vehicle to close the docket.
• Claim viability concerns: After filing, Metronome’s counsel may have identified weaknesses in claim mapping — infringement reads on accused products, prior art threatening patent validity, or claim construction vulnerabilities — that made continued prosecution untenable.
• Commercial resolution: Business-level resolution between the parties — including product reformulation, market exit by the defendant, or licensing terms — could have rendered continued litigation unnecessary.
• Defendant’s early litigation response: Defense motions or informal communications may have surfaced arguments (e.g., non-infringement positions, invalidity contentions under 35 U.S.C. §§ 102/103) that materially shifted Metronome’s cost-benefit calculus.

Because the dismissal was with prejudice and docket entry [17] reflects a plaintiff-initiated notice rather than a settlement agreement filed with the court, the specific terms — if any existed — remain confidential. Specific financial terms were not disclosed in available case records.

Legal Significance

This case establishes **no direct precedent** on the merits of cannabis topical patent claims under US10653736B2. However, its rapid conclusion contributes to the broader pattern of cannabis patent assertions that resolve before claim construction — a trend reflecting the still-unsettled nature of cannabis IP validity landscapes, particularly given evolving USPTO examination standards for botanical drug formulations.